Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28568597 | 0.80 | KDM4E (0.48) | MGAMGAASIMGAM2HTT | |
| SCHEMBL15693960 | 0.80 | LDHA (0.42) | ALDH1A1KDM4EKDM6BKDM5CEGLN1 | |
| SCHEMBL9577628 | 0.77 | GAA (0.39) | MGAMGAASIMGAM2HTT | |
| SCHEMBL1785020 | 0.75 | — | — | |
| SCHEMBL1785021 | 0.75 | — | — | |
| SCHEMBL10875817 | 0.74 | KDM4E (0.39) | MGAMGAASIMGAM2HTT | |
| SCHEMBL10631628 | 0.74 | KDM4E (0.39) | MGAMGAASIMGAM2HTT | |
| SCHEMBL1703734 | 0.73 | — | — | |
| SCHEMBL1703735 | 0.73 | — | — | |
| SCHEMBL13623231 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023636-B2 | Microorganisms and methods for the biosynthesis of propylene | GENOMATICA, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-7838519-B2 | Maytansinoid analogs as antitumor agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080249085-A1 | Maytansinoid Analogs as Antitumor Agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249085-A1 | Maytansinoid Analogs as Antitumor Agents | AREG, HASPIN, NTPCR | MGAM 2331/4885GAA 104/4885SI 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.